Astrazeneca (AZN) Current Assets (2009 - 2026)

Astrazeneca has reported Current Assets for 18 years, with the latest figure at $28.0 billion in Q2 2026.

• On a quarterly basis, Current Assets fell 3.37% year-over-year to $28.0 billion in Q2 2026; TTM through Jun 2026 was $28.0 billion, a 3.37% decrease from a year earlier, with the FY2025 full-year figure at $28.7 billion, up 11.21% from the prior year.
• Current Assets was $28.0 billion for Q2 2026 at Astrazeneca, down from $29.6 billion in the prior quarter.
• The five-year high for Current Assets was $29.9 billion in Q3 2025, with the low at $20.2 billion in Q3 2022.
• Average Current Assets over 5 years is $25.1 billion, with a median of $25.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Current Assets dropped 24.23% in 2022, then grew 23.95% in 2025.
• Over 5 years, Current Assets stood at $22.6 billion in 2022, then increased by 10.89% to $25.1 billion in 2023, then increased by 3.09% to $25.8 billion in 2024, then increased by 11.21% to $28.7 billion in 2025, then dropped by 2.64% to $28.0 billion in 2026.
• The last three Current Assets figures came in at $28.0 billion (Q2 2026), $29.6 billion (Q1 2026), and $28.7 billion (Q4 2025), per Business Quant data.